Posted: Fri., May 7, 1999

Televisa takes Slim chance

Businessman holds 24% of stake

MEXICO CITY -- The long restructuring saga at Televisa holding company Televicentro seems to have reached a close with the entrance of Carlos Slim, Latin America's richest businessman, as a 24% shareholder.

Sinca Inbursa, a Mexican venture capital fund controled by Slim, has entered Televicentro as a passive investor, with no voting rights. Financial terms were not disclosed, but Inbursa is said to have paid $350 mil in a debt-for-equity swap.

The door to Televicentro was opened to outside investors last month, when the Aleman family announced they were selling their 14% stake (Daily Variety, April 7).

CEO Emilio Azcarraga now holds a 51% stake, which is believed to include shares owned by his three sisters, while his cousin, Alejandro Burillo, the company's No. 2, has upped his stake from 14% to 25%.

Another set of cousins, the Diez Barroso family, had entered Televicentro on a short-term basis with 21%, which they have also sold.

The Inbursa deal does not preclude a later sale to a strategic, possibly foreign partner, said Leonardo Simpser of Deutsche Morgan. Telefonica de Espana, for one, previously expressed an interest.

Televisa stock closed up $5 Thursday to $47.75.


TALKBACK:

Have an opinion about this article? Be the first to comment




Q What are the top 3 things affecting our industry today?
A. Aaron - 1. New Media: The internet has exploded not only affecting sales in the music industry, bu... more >


Submit this form
Tressa, one of the many stars of A&E's 'Intervention,' talks about her lengthy battle with methamphetamine. ; reality show; intervention; A&E; emmy contenders; drug addicts; variety; Interviews with Erick McCormack, Daniel Dae Kim & Christa Miller, stars of A&E's new sci-fi thriller, 'The Andromeda Strain.'; Erick McCormack; A&E; tv; sci-fi; The Andromeda Strain; variety; Daniel Dae Kim & Christa Miller;


© 2008 Reed Business Information, a division of Reed Elsevier Inc. All rights reserved. Use of this website is subject to its Terms & Conditions of Use. View our Privacy Policy.